Oral Sessions
（Day1, Day2, Day3, Day4）
Poster Presentations
（Day1, Day2, Day3, Day4）
Luncheon Seminars
（Day1, Day2, Day3, Day4）
Poster Presentations
- Day 1, May 15（Tue.） Poster
-
1P-46 PDF
Serum biomarkers for evaluation of thyroid cancer prognosis after radioactive iodine treatment
Differentiated thyroid cancer (DTC) patients are at increased risk of distant metastases and locoregional recurrence. The standard therapy for DTC is radioactive iodine (131I) treatment (RIT) into the bloodstream in order to induce thyroid ablation and manage locoregional and metastatic spread. The known adverse effects of RIT are inflammation, such as sialadenitis and the subsequent reduction of normal tissue function, such as xerostomia. The aim of the present study is to search the effective serum biomarker for prognosis after radioactive iodine treatment and its adverse effect using CE-TOF/MS. Eight DTC patients were subjected to thyroid hormone withdrawal and iodine restriction, such as radioactive iodine remnant ablation, for 2 weeks before each treatment. Peripheral blood was collected from DTC patients before and after RIT, and analyzed by CE-TOF/MS. Approximately 900 known metabolites were detected, and a significantly increasing of TCA cycle related metabolites were observed after RIT incomparison to before RIT. Furthermore, the variation of these molecules has an individual variety to the influence of radiation damage. Therefore, it was suggested that TCA cycle related molecules is one of the marker for DTC prognosis.